Metsera reports fourth quarter and full year 2024 financial results and continued portfolio progress

Met-097i, a fully biased, monthly, ultra-long acting glp-1 receptor agonist, is being studied in multiple phase 2b clinical trials with read-outs beginning mid-2025

MTSR Ratings Summary

MTSR Quant Ranking